Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects

Table 1

Correlation between prostate biopsy adverse effects and pharmacological treatment for benign prostatic hyperplasia.

Adverse effects*	Control 𝑛=140	Group 1 𝑛=33	𝑃	Group 2 𝑛=5	𝑃	Group 3 𝑛=12	𝑃
Hematuria	82 (59%)	12 (36%)	0.01	1 (20%)	0.02	1 (8%)	0.003
Hematospermia	42 (30%)	6 (18%)	0.2	3 (60%)	0.1	2 (17%)	0.5
Hematochezia	16 (11%)	4 (12%)	1	1 (20%)	0.5	1 (8%)	1
Urethrorrhagia	12 (9%)	6 (18%)	0.1	0 (zero)	1	1 (8%)	1
Fever	4 (3%)	1 (3%)	1	0 (zero)	1	0 (zero)	1
Pain**	16 (11%)	2 (6%)	0.5	1 (20%)	0.5	1 (8%)	1

Control: patients not using any medication (control/reference). Group 1: patients using alpha-blockers, exclusively. Group 2: patients using 5-alpha-reductase, exclusively. Group 3: patients using both medications. 𝑃 value ≤0.05 was considered significant (bold).*Lasting more than one week after the procedure. **Visual analog scale (VAS) ≥5, 24 h after the procedure.